Clinical Trial

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Study acronym: IV IgG
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-02-13; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-07-31
Trial Details
NCT Number NCT06834035
Lead Sponsor M. Peter Marinkovich
Collaborators: Epidermolysis Bullosa Research Partnership
Conditions Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Enrollment 8 participants
Start Date 2025-08-04
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-05